SkylineDx Announces Grant of European Patent and Advances in Melanoma Diagnosis and Treatment

Source: PR News Wire, January 2024

ROTTERDAM, Netherlands and SAN DIEGO, Jan. 9, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company focused on the research and development of molecular diagnostics, is excited to announce that the European Patent Office (EPO) has granted European Patent No. 3827101, marking a groundbreaking advancement in the field of cancer diagnostics and personalized treatment.

This patent introduces innovative approaches to classify and treat individuals afflicted with primary cutaneous melanoma based on the expression levels of gene expression signature , providing the foundation for highly precise diagnosis and personalized treatment plans.

Dharminder Chahal, CEO of SkylineDx, expressed his pride in this achievement, stating, “Obtaining the European Patent is a testament to SkylineDx’s commitment to advancing the field of melanoma diagnosis and treatment. It is a recognition of the important work that our team is doing in collaboration with Mayo Clinic. Our innovative methods for classifying and treating primary cutaneous melanoma represent a significant leap forward in providing personalized care for patients. We are proud to contribute to the improvement of patient outcomes and the advancement of medical research.
READ THE ORIGINAL FULL ARTICLE